We found that self-reported coffee drinking and caffeine consumption from beverages were associated with a lower risk of advanced hepatic fibrosis in patients with chronic HCV but had no association with degree of hepatic inflammation. An average daily intake of an estimated 100 mg of caffeine from coffee, tea, or soda was associated with an approximately one-third reduction in odds of advanced fibrosis, although higher intake did not seem to confer any additional benefit. Interestingly, tea intake in those who did not consume coffee also was found to be associated with a decreased risk of advanced fibrosis. The inverse association between 100 mg or more of caffeine intake daily and advanced hepatic fibrosis remained significant after adjustment for potential confounders (eg, age, alcohol use, BMI, MELD score, and metabolic syndrome), and was attenuated when adjusted for HOMA-IR status. The inverse association between caffeine consumption and degree of fibrosis was found using caffeine intake data from the year preceding study recruitment, however, lifetime caffeine intake did not seem to influence this relationship.
Our finding that caffeine intake is associated with a decreased risk of advanced HCV-related fibrosis is in line with several other studies that have suggested a beneficial effect of caffeine on hepatic function in various liver diseases, including nonalcoholic steatohepatitis, alcoholic liver disease, and primary sclerosing cholangitis.
4x4Klatsky, A.L. and Armstrong, M.A. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992; 136: 1248–1257
PubMedSee all References, 6x6Tanaka, K., Tokunaga, S., Kono, S. et al. Coffee consumption and decreased serum γ-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol. 1998; 27: 438–443
CrossRef | PubMed | Scopus (97)See all References, 10x10Ruhl, C.E. and Everhart, J.E. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2005; 128: 24–32
Abstract | Full Text | Full Text PDF | PubMed | Scopus (131)See all References, 33x33Birerdinc, A., Stepanova, M., Pawloski, L. et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012; 35: 76–82
CrossRef | PubMed | Scopus (32)See all References, 34x34Chen, S., Teoh, N.C., Chitturi, S. et al. coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection?. J Gastroenterol Hepatol. 2014; 29: 435–441
CrossRef | PubMed | Scopus (5)See all References, 35x35Andersen, I.M., Tengesdal, G., Lie, B.A. et al. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2014; 12: 1019–1028
Abstract | Full Text | Full Text PDF | PubMed | Scopus (5)See all References, 36x36Lammert, C., Juran, B.D., Schlicht, E. et al. Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2014; 12: 1562–1568
Abstract | Full Text | Full Text PDF | PubMed | Scopus (3)See all References, 37x37Corrao, G., Lepore, A.R., Torchio, P. et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Eur J Epidemiol. 1994; 10: 657–664
CrossRef | PubMed | Scopus (85)See all References, 38x38Klatsky, A.L., Morton, C., Udaltsova et al. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med. 2006; 166: 1190–1195
CrossRef | PubMed | Scopus (105)See all References It also is consistent with an analysis of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial, which found that daily coffee consumption was associated with slower disease progression in patients with chronic HCV-related bridging fibrosis and cirrhosis who had failed to respond to treatment with pegylated interferon and ribavirin. However, in contrast to our findings, which suggest no substantial additional benefit of caffeine intake of 100 mg/day or more, they found a dose-dependent response with coffee drinkers who reported 3 or more cups daily experiencing the greatest (∼53%) reduced risk of disease progression (ie, to decompensation or HCC) compared with non–coffee drinkers.
16x16Freedman, N.D., Everhart, J.E., Lindsay, K.L. et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009; 50: 1360–1369
CrossRef | PubMed | Scopus (81)See all References16 We hypothesize that the primary explanation for this discrepancy is the difference in the spectrum of HCV-related liver disease among studies because the HALT-C trial was restricted to cirrhotic patients, whereas our study population included the full spectrum of HCV-related liver disease. However, other differences in study design and among populations also may have contributed to this discrepancy. Our results suggesting that a modest dose of caffeine intake (∼100 mg/d) was associated with a significantly reduced risk of advanced fibrosis in veterans with chronic HCV are similar to an earlier comparable pilot study in 91 HCV-positive veterans.
39x39White, D.L., Richardson, P.A., Al-Saadi, M. et al. Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. Dig Dis Sci. 2011; 56: 1835–1847
CrossRef | PubMedSee all References39 The consistency in these results over time further supports the internal validity of our findings.
In contrast to our results, Costentin et al
17x17Costentin, C.E., Roudot-Thoraval, F., Zafrani, E.S. et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol. 2011; 54: 1123–1129
Abstract | Full Text | Full Text PDF | PubMed | Scopus (30)See all References17 found no significant protective association in their study of 238 French patients with treatment-naive chronic HCV. However, they did find that daily caffeine consumption of more than 408 mg (equivalent to ≥3 cups of coffee) was an independent predictor of lower histologic activity grade of hepatitis. Several factors may explain this discrepancy, including differences in populations such as higher average caffeine intake but lower rates of obesity and alcohol abuse overall in the French study population, differences in methods of estimating caffeine intake, and known substantial variability in caffeine found in coffee and tea based on methods of production and preparation.
Our findings suggest that a total combined caffeine intake or dose of 100 mg or more daily is associated with a significant decrease in risk of hepatic fibrosis, but without further risk reduction with higher coffee or caffeine doses. However, the optimal hepatoprotective dose of caffeine in HCV-infected patients overall is unclear. Although some studies suggested the strongest benefit from coffee consumption was at 3 or more cups daily, or approximately 400 mg of caffeine,
16x16Freedman, N.D., Everhart, J.E., Lindsay, K.L. et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009; 50: 1360–1369
CrossRef | PubMed | Scopus (81)See all References, 17x17Costentin, C.E., Roudot-Thoraval, F., Zafrani, E.S. et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol. 2011; 54: 1123–1129
Abstract | Full Text | Full Text PDF | PubMed | Scopus (30)See all References other studies reported a significant reduction in the risk in HCV-related hepatic fibrosis associated with an intake of 1 or 2 cups of cups of coffee daily.
11x11Modi, A.A., Feld, J.J., Park, Y. et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010; 51: 201–209
CrossRef | PubMed | Scopus (84)See all References, 40x40Machado, S.R., Parise, E.R., and de Carvalho, L. Coffee has hepatoprotective benefits in Brazilian patients with chronic hepatitis C even in lower daily consumption than in American and European populations. Braz J Infect Dis. 2014; 18: 170–176
CrossRef | PubMed | Scopus (1)See all References Our results suggest that as little as 100 mg or more of caffeine daily may be beneficial in a general HCV-infected population with a high prevalence of other risk factors for advanced liver disease. However, our power to evaluate the benefit of higher intake likely was limited by the small number of our study participants who reported drinking higher quantities of caffeinated beverages. Nonetheless, if validated in other HCV-infected populations in the United States, our results suggest that a relatively low (and therefore potentially more tolerable dose) of caffeine, particularly from caffeinated coffee and possibly from tea, may convey a substantial reduction in fibrosis progression.
Several mechanisms have been suggested by which caffeine may act to reduce the risk of advanced fibrosis.
41x41Kumari, R. and Kim, W.R. Coffee: a panacea or snake oil for the liver?. Clin Gasteroenterol Hepatol. 2014; 12: 1569–1571
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1)See all References41 Caffeine functions as a nonselective adenosine-receptor antagonist and a phosphodiesterase inhibitor with a broad range of attendant effects including inhibition of growth factors that contribute to hepatic fibrosis.
42x42Peng, Z., Fernandez, P., Wilder, T. et al. Ecto-5′-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J. 2008; 22: 2263–2272
CrossRef | PubMed | Scopus (49)See all References, 43x43Arauz, J., Moreno, M.G., Cortes-Reynosa, P. et al. Coffee attenuates fibrosis by decreasing the expression of TGF-β and CTGF in a murine model of liver damage. J Appl Toxicol. 2013; 33: 970–979
CrossRef | PubMed | Scopus (14)See all References, 44x44Gressner, O.A., Lahme, B., Rehbein, K. et al. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol. 2008; 49: 758–767
Abstract | Full Text | Full Text PDF | PubMed | Scopus (61)See all References Caffeine is metabolized in the liver primarily by CYP1A2, with reduced expression of CYP1A2 correlated with fibrosis progression in a study of HCV patients.
45x45Nakai, K., Tanaka, H., Hanada, K. et al. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos. 2008; 36: 1786–1793
CrossRef | PubMed | Scopus (41)See all References45 Caffeine also has been shown in animal and in vitro studies to act as an antioxidant.
46x46Devasagayam, T.P., Kamat, J.P., Mohan, H. et al. Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim Biophys Acta. 1996; 1282: 63–70
CrossRef | PubMed | Scopus (149)See all References46 Other studies have suggested that the primary hepatoprotective benefit of caffeine is associated with caffeinated coffee intake.
4x4Klatsky, A.L. and Armstrong, M.A. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992; 136: 1248–1257
PubMedSee all References, 6x6Tanaka, K., Tokunaga, S., Kono, S. et al. Coffee consumption and decreased serum γ-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol. 1998; 27: 438–443
CrossRef | PubMed | Scopus (97)See all References, 11x11Modi, A.A., Feld, J.J., Park, Y. et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010; 51: 201–209
CrossRef | PubMed | Scopus (84)See all References, 16x16Freedman, N.D., Everhart, J.E., Lindsay, K.L. et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009; 50: 1360–1369
CrossRef | PubMed | Scopus (81)See all References, 47x47Gallus, S., Tavani, A., Negri, E. et al. Does coffee protect against liver cirrhosis?. Ann Epidemiol. 2002; 12: 202–205
Abstract | Full Text | Full Text PDF | PubMed | Scopus (60)See all References However, this could be the effect of generally higher daily cumulative caffeine intake in coffee drinkers compared with consumers of other caffeinated beverages overall, or with pharmacodynamic differences in effects given the substantial differences in caffeine per unit intake of caffeinated coffee in comparison with tea or soda. Finally, it also has been postulated that other constituents of coffee, such as diterpenes, polyphenols, kahweol, and cafestrerol, which have anti-oxidant activity, also may be responsible for the particular hepatoprotective effect of coffee.
48x48Scalbert, A. and Williamson, G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000; 130: 2073S–2085S
PubMedSee all References, 49x49Cavin, C., Holzhaeuser, D., Scharf, G. et al. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol. 2002; 40: 1155–1163
CrossRef | PubMed | Scopus (194)See all References, 50x50Huber, W.W., Scharf, G., Rossmanith, W. et al. The coffee components kahweol and cafestol induce gamma-glutamylcysteine synthetase, the rate limiting enzyme of chemoprotective glutathione synthesis, in several organs of the rat. Arch Toxicol. 2002; 75: 685–694
CrossRef | PubMedSee all References, 51x51Lee, C. Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation. Clin Chim Acta. 2000; 295: 141–154
CrossRef | PubMed | Scopus (98)See all References However, studies, including ours, have not shown that decaffeinated coffee exerts the same effect on liver disease as caffeinated coffee.
11x11Modi, A.A., Feld, J.J., Park, Y. et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010; 51: 201–209
CrossRef | PubMed | Scopus (84)See all References, 47x47Gallus, S., Tavani, A., Negri, E. et al. Does coffee protect against liver cirrhosis?. Ann Epidemiol. 2002; 12: 202–205
Abstract | Full Text | Full Text PDF | PubMed | Scopus (60)See all References
Inflammation is another known risk factor for progression to fibrosis in chronic HCV,
52x52Leandro, G., Mangia, A., Hui, J. et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006; 130: 1636–1642
Abstract | Full Text | Full Text PDF | PubMed | Scopus (324)See all References52 and the role of coffee as an anti-inflammatory agent in nonliver diseases has been suggested.
2x2Andersen, L.F., Jacobs, D.R. Jr., Carlsen, M.H. et al. Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women's Health Study. Am J Clin Nutr. 2006; 83: 1039–1046
PubMedSee all References2 In our study, we found no significant association between caffeine intake and the severity of hepatic inflammation, in line with findings by Freedman et al
16x16Freedman, N.D., Everhart, J.E., Lindsay, K.L. et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009; 50: 1360–1369
CrossRef | PubMed | Scopus (81)See all References16 that coffee intake was not associated with lower baseline hepatic inflammation. Prior work has shown that insulin resistance worsens hepatic inflammation in HCV patients,
18x18Negro, F. Insulin resistance and HCV: will new knowledge modify clinical management?. J Hepatol. 2006; 45: 514–519
Abstract | Full Text | Full Text PDF | PubMed | Scopus (48)See all References18 and a meta-analysis suggested that part of the hepatoprotective effect of coffee in part may be related to an associated reduction in insulin resistance and type 2 diabetes mellitus.
19x19Van Dam, R.M. and Hu, F.B. Coffee consumption and risk of type 2 diabetes a systematic review. JAMA. 2005; 294: 97–104
CrossRef | PubMed | Scopus (346)See all References19 In our study, caffeine intake was associated inversely with insulin resistance via the surrogate marker of the HOMA-IR score in nondiabetic participants.
Therefore, one potential mechanism linking caffeine intake or the associated lifestyle with decreased risk of advanced fibrosis is the amelioration of insulin resistance. Further studies are needed to better elucidate the underlying pathophysiological mechanisms by which caffeine or its metabolites and other constituents of coffee account for the positive health benefits seen particularly with caffeinated coffee consumption in liver disease patients.
We found that an average of 100 mg or more of caffeine daily from sodas and teas does not have the same protective effect as 100 mg or more of caffeine daily from combined sources (coffee, tea, soda) or from coffee alone, suggesting that caffeine alone may not entirely explain the effect of coffee on liver disease. Although several prior studies have not shown a lower risk of liver disease progression in those who consume caffeine from noncoffee sources such as tea
4x4Klatsky, A.L. and Armstrong, M.A. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992; 136: 1248–1257
PubMedSee all References, 11x11Modi, A.A., Feld, J.J., Park, Y. et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010; 51: 201–209
CrossRef | PubMed | Scopus (84)See all References, 16x16Freedman, N.D., Everhart, J.E., Lindsay, K.L. et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009; 50: 1360–1369
CrossRef | PubMed | Scopus (81)See all References, 47x47Gallus, S., Tavani, A., Negri, E. et al. Does coffee protect against liver cirrhosis?. Ann Epidemiol. 2002; 12: 202–205
Abstract | Full Text | Full Text PDF | PubMed | Scopus (60)See all References or soda,
47x47Gallus, S., Tavani, A., Negri, E. et al. Does coffee protect against liver cirrhosis?. Ann Epidemiol. 2002; 12: 202–205
Abstract | Full Text | Full Text PDF | PubMed | Scopus (60)See all References47 this could be related to differing caffeine content, other ingredients in addition to caffeine that may be partly responsible for the proposed hepatoprotective effects of coffee, or to substantial differences in study design or populations. Among the 413 noncoffee drinkers in our current study, intake of at least 1 cup of caffeinated tea daily was more common in the mild fibrosis control group, and after controlling for potential confounders, this significance was even more pronounced. This finding provides further evidence for the protective role of caffeine from any source against the progression of liver disease.
In regards to soda, an understudied source of caffeine, we found consumption of more than 1 can of caffeinated soda daily to be associated with a decreased risk of hepatic fibrosis, supporting that caffeine likely plays a major role in coffee’s hepatoprotective effects. On multivariate nonstratified analysis, more than 1 can of caffeinated soda daily remained significantly associated with a decreased risk of hepatic fibrosis, with some attenuation after controlling for possible confounders (age, alcohol, BMI, MELD score, and the presence of the metabolic syndrome). When adjusted for self-reported diabetes and HOMA-IR scores, there was a nonsignificant trend toward a decreased risk of fibrosis (adjusted OR, 0.75; 95% CI, 0.55–1.02;
P = .063). However, in analyzing soda intake in the subgroup of non–coffee drinkers (n = 413), there was no notable difference in the risk of hepatic fibrosis (
P = .41). The findings may indicate that caffeine from soda has hepatoprotective effects, but we cannot exclude the possibility that increased soda consumption reflects an increased intake of caffeinated beverages overall, including coffee. As with coffee, decaffeinated tea and soda were not found to be associated with a decreased risk of liver disease.
Our study had several strengths, including being a large study that examined the association between caffeinated coffee intake and HCV-related liver disease, and adds to the limited research in US populations. It also adds to the sparse literature on the effects of caffeinated tea and soda intake. In addition, we obtained and analyzed information on the consumption of decaffeinated coffee, tea, and soda to better elucidate the mechanisms underlying the potential hepatoprotective effects of caffeine and coffee on liver disease. Finally, our novel use of a validated noninvasive marker for liver fibrosis, the validated FibroSURE test,
26x26Halfon, P., Bourliere, M., Deydier, R. et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol. 2006; 101: 547–555
CrossRef | PubMed | Scopus (109)See all References, 27x27Ngo, Y., Munteanu, M., Messous, D. et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem. 2006; 52: 1887–1896
CrossRef | PubMed | Scopus (159)See all References, 28x28Morali, G., Maor, Y., Klar, R. et al. Fibrotest-Actitest: the biochemical marker of liver fibrosis–the Israeli experience. Isr Med Assoc J. 2007; 9: 588–591
PubMedSee all References, 29x29Imbert-Bismut, F., Ratziu, V., Pieroni, L. et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357: 1069–1075
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1004)See all References, 30x30Grigorescu, M., Rusu, M., Neculoiu, D. et al. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience. J Gastrointest Liver Dis. 2007; 16: 31–37
PubMedSee all References, 31x31Poynard, T., Imbert-Bismut, F., Ratziu, V. et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002; 9: 128–133
CrossRef | PubMed | Scopus (188)See all References, 32x32Poynard, T., Munteanu, M., Ngo, Y. et al. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol Clin Biol. 2010; 34: 388–396
CrossRef | PubMed | Scopus (20)See all References allowed evaluation of a large and diverse HCV patient group, many of whom would have been precluded from biopsy based on highly prevalent comorbid conditions in this population.
Our study also had some limitations. Given the observational retrospective nature of the study, a causal association cannot be made. We studied a select patient population of HCV-monoinfected, largely male veterans, and therefore the findings may not be applicable to women with HCV or co-infected patients. Beverage consumption was self-reported, and caffeine intake was estimated based on the average reported intake, and therefore may not accurately reflect the actual intake given the known variability in caffeine levels in coffee and tea of the same type owing to differences in production and preparation. However, any misclassification should be nondifferential (ie, similar among cases and controls) and therefore any possible bias should be toward the null or finding of no association. A potential for reverse causality may be present if patients with more advanced liver disease are averse to drinking caffeine-containing beverages including coffee; however, we did not enroll patients with decompensated liver disease. We also found that the decreased risk of advanced fibrosis with an average daily intake of 100 mg or more of caffeine or 1 or more cups of tea in non–coffee drinkers remained significant or nearly significant after adjusting for MELD scores and insulin resistance. In total, 40% of our participants were classified as marijuana users, and we found no significant association with the degree of hepatic fibrosis or inflammation and marijuana use. However, we did not have information on the duration or frequency of marijuana use, a limitation of our study.
53x53Hézode, C., Roudot-Thoraval, F., Nguyen, S. et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005; 42: 63–71
CrossRef | PubMed | Scopus (163)See all References53 Prior studies also have suggested women who consume alcohol may have a less pronounced response to the hepatoprotective effects of caffeine as measured by γ-glutamyltransferase levels,
54x54Danielsson, J., Kangastupa, P., Laatikainen, T. et al. Dose- and gender-dependent interactions between coffee consumption and serum GGT activity in alcohol consumers. Alcohol Alcohol. 2013; 48: 303–307
CrossRef | PubMed | Scopus (5)See all References54 and in animal models, females may recover more slowly from hepatic injury than males.
55x55Wang, Y., Ye, F., Ke, Q. et al. Gender-dependent histone deacetylases injury may contribute to differences in liver recovery rates of male and female mice. Transplant Proc. 2013; 45: 463–473
Abstract | Full Text | Full Text PDF | PubMedSee all References55 Our study participants were largely male (n = 888), with only 22 females represented. As such, our study lacked the statistical power to find a notable gender-specific difference in the hepatoprotective effects of caffeine or coffee.
In conclusion, we found that an average daily intake of 100 mg or more of caffeine was associated with a lower risk of hepatic fibrosis in a general clinical population with chronic HCV infection. We further showed that in non–coffee drinkers, daily caffeinated tea intake also may protect against progressive liver disease in this population. Our study further suggests that caffeinated coffee overall and caffeinated tea in non–coffee drinkers likely provide the most benefit in liver disease compared with other caffeinated beverages or decaffeinated coffee. Future prospective studies are warranted to determine the optimal dose and preparation of caffeinated beverage intake that could be safely and tolerably recommended for prevention of progressive liver disease in HCV patients in routine clinical practice.